Literature DB >> 11151887

Porphyria cutanea tarda in Brazilian patients: association with hemochromatosis C282Y mutation and hepatitis C virus infection.

A L Martinelli1, M A Zago, A M Roselino, A B Filho, M G Villanova, M Secaf, M H Tavella, L N Ramalho, S Zucoloto, R F Franco.   

Abstract

OBJECTIVE: Porphyria cutanea tarda (PCT) is commonly associated with iron overload and hepatitis C virus (HCV) infection. Association between hemochromatosis C282Y or H63D mutations and PCT has been observed, although not uniformly, and iron overload is also commonly found in chronic HCV hepatitis. The aim of the present study was to investigate the frequency of C282Y and H63D mutations and HCV infection in Brazilian patients with PCT and their relationship with iron overload.
METHODS: Twenty-three patients (19 men) aged 39.6 +/- 11.1 yr were studied. All had dermatological lesions of PCT and high levels of urinary uroporphyrin. HCV infection and iron overload were investigated. DNA samples were analyzed for the presence of HFE mutations.
RESULTS: The frequency of C282Y was significantly higher in PCT patients than in 278 healthy individuals (17.4% vs 4%, odds ratio = 5.1, 95% confidence interval 1.5-17.6, p = 0.02), whereas no difference was observed regarding the H63D mutation (30.4% vs 31%, odds ratio = 1, 95% confidence interval 0.4-2.4, p = 1). Biochemical tests in PCT patients showed iron overload with transferrin saturation = 47.3 +/- 20.7% and ferritin = 566.8 +/- 425 ng/ml. Fifteen of 23 (65.2%) patients had HCV infection and alcohol ingestion was observed in 17 of 23 (73.9%).
CONCLUSIONS: PCT patients exhibited evidence of iron overload, a high frequency of HCV, and an association with C282Y mutation. These data further support the notion that both acquired and inherited factors contribute to the occurrence of PCT, and indicate that screening for C282Y may be justified in PCT patients.

Entities:  

Mesh:

Year:  2000        PMID: 11151887     DOI: 10.1111/j.1572-0241.2000.03369.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  7 in total

1.  Hepatic iron quantitation and its relationship with disease measures and histologically assessed iron content.

Authors:  Shabbar Sajjad; Moises Garcia; Ahmed Malik; David H Van Thiel
Journal:  Dig Dis Sci       Date:  2007-10-13       Impact factor: 3.199

2.  Autoantibodies to human cytosol: a marker of sporadic porphyria cutanea tarda.

Authors:  Y Ma; A L Fracanzani; M Sampietro; M Mattioli; P Cheeseman; R Williams; G Mieli-Vergani; D Vergani; S Fargion
Journal:  Clin Exp Immunol       Date:  2001-10       Impact factor: 4.330

Review 3.  Hepatitis C, porphyria cutanea tarda and liver iron: an update.

Authors:  F Ryan Caballes; Hossein Sendi; Herbert L Bonkovsky
Journal:  Liver Int       Date:  2012-04-17       Impact factor: 5.828

4.  Associations among behavior-related susceptibility factors in porphyria cutanea tarda.

Authors:  Sajid Jalil; James J Grady; Chul Lee; Karl E Anderson
Journal:  Clin Gastroenterol Hepatol       Date:  2009-11-27       Impact factor: 11.382

Review 5.  HFE gene in primary and secondary hepatic iron overload.

Authors:  Giada Sebastiani; Ann-P Walker
Journal:  World J Gastroenterol       Date:  2007-09-21       Impact factor: 5.742

6.  Precipitating factors of porphyria cutanea tarda in Brazil with emphasis on hemochromatosis gene (HFE) mutations. Study of 60 patients.

Authors:  Fatima Mendonça Jorge Vieira; Maria Cristina Nakhle; Clarice Pires Abrantes-Lemos; Eduardo Luiz Rachid Cançado; Vitor Manoel Silva dos Reis
Journal:  An Bras Dermatol       Date:  2013 Jul-Aug       Impact factor: 1.896

7.  The D519G Polymorphism of Glyceronephosphate O-Acyltransferase Is a Risk Factor for Familial Porphyria Cutanea Tarda.

Authors:  Colin P Farrell; Jessica R Overbey; Hetanshi Naik; Danielle Nance; Gordon D McLaren; Christine E McLaren; Luming Zhou; Robert J Desnick; Charles J Parker; John D Phillips
Journal:  PLoS One       Date:  2016-09-23       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.